NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VERV

Verve Therapeutics Inc

Jul 01 • 10:29AM ET

11.20

Dollar change -0.03
Percentage change -0.27	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM EDIT CRBU DTIL SGMO CLLS QURE BLRX

| Held by: IWM VTI XBI IWN VXF IBB SCHA IDNA DFAS IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	26.23%	Shs Outstand	88.80M	Perf Week	0.27%
Market Cap	998.41M	Forward P/E	-	EPS next Y	-2.82	Insider Trans	-0.10%	Shs Float	65.76M	Perf Month	151.69%
Enterprise Value	569.97M	PEG	-	EPS next Q	-0.69	Inst Own	74.02%	Short Float	27.37%	Perf Quarter	145.08%
Income	-181.01M	P/S	16.75	EPS this Y	-4.53%	Inst Trans	10.59%	Short Ratio	3.34	Perf Half Y	77.78%
Sales	59.61M	P/B	2.10	EPS next Y	-14.93%	ROA	-26.89%	Short Interest	18.00M	Perf YTD	98.58%
Book/sh	5.33	P/C	2.01	EPS next 5Y	-0.31%	ROE	-34.26%	52W High	11.40 -1.80%	Perf Year	135.29%
Cash/sh	5.58	P/FCF	-	EPS past 3/5Y	1.84% -42.43%	ROIC	-34.05%	52W Low	2.86 290.97%	Perf 3Y	-33.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	88.53%	Volatility	0.96% 6.29%	Perf 5Y	-
Dividend TTM	-	EV/Sales	9.56	EPS Y/Y TTM	26.65%	Oper. Margin	-349.68%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.84	Sales Y/Y TTM	271.44%	Profit Margin	-303.64%	RSI (14)	83.55	Recom	2.75
Dividend Gr. 3/5Y	- -	Current Ratio	9.84	EPS Q/Q	40.38%	SMA20	30.45%	Beta	2.24	Target Price	12.86
Payout	-	Debt/Eq	0.14	Sales Q/Q	479.03%	SMA50	77.86%	Rel Volume	0.59	Prev Close	11.23
Employees	274	LT Debt/Eq	0.12	Earnings	May 14 BMO	SMA200	87.44%	Avg Volume	5.39M	Price	11.20
IPO	Jun 17, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	45.65% 266.09%	Trades		Volume	621,683	Change	-0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Apr-08-24	Initiated	H.C. Wainwright	Buy	$15
Apr-13-23	Initiated	Canaccord Genuity	Buy	$29
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral	$21
Dec-15-22	Initiated	Goldman	Sell	$13
Oct-06-22	Initiated	Credit Suisse	Neutral	$48
Aug-25-22	Upgrade	Stifel	Hold → Buy	$32 → $56
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$48
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$42
Sep-24-21	Initiated	Stifel	Hold	$58
Jul-12-21	Initiated	William Blair	Outperform	$92
Jul-12-21	Initiated	JP Morgan	Neutral	$50
Jul-12-21	Initiated	Jefferies	Buy	$72
Jul-12-21	Initiated	Guggenheim	Buy	$84

Show Previous Ratings

Jun-27-25 09:53AM	BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside (Investing.com)
Jun-23-25 01:40AM	Lilly To Acquire Verve For One-Time Cardiovascular Treatments (Insider Monkey)
Jun-20-25 01:07PM	Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week (Motley Fool)
Jun-19-25 10:23AM	What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? (Zacks)
09:45AM	SanDisk initiated, Analog Devices upgraded: Wall Streets top analyst calls (TipRanks)
09:55AM	Loading…
Jun-18-25 09:55AM	Verve Therapeutics downgraded to Hold from Buy at Canaccord (TipRanks)
09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 05:49PM	Podcast: U.S. Stocks Slip as Israel-Iran Conflict Continues (The Wall Street Journal) +81.50%
04:36PM	Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar (The Wall Street Journal)
04:34PM	These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More (Barrons.com)
03:59PM	Solar stocks, Eli Lilly & Verve, PureCycle: Trending Tickers (Yahoo Finance Video)
02:47PM	These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More (Barrons.com)
01:28PM	Eli Lilly lands bargain deal to acquire Verve Therapeutics for $1.3bn (Pharmaceutical Technology)
12:12PM	Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly (Zacks)
12:03PM	Top Stock Movers Now: Enphase Energy, T-Mobile US, Jabil, and More (Investopedia)
11:08AM	Loading…
11:08AM	Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion (GuruFocus.com)
11:05AM	Why Verve Therapeutics Stock Is Skyrocketing Today (Motley Fool)
10:53AM	Stocks to Watch Tuesday: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar (The Wall Street Journal)
10:02AM	Eli Lillys $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. (Barrons.com)
09:53AM	T-Mobile & Softbank, solar, Eli Lilly & Verve: Trending Tickers (Yahoo Finance Video)
09:15AM	Verve Therapeutics Skyrockets - Pulling Gene-Editing Stocks Higher - On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
08:14AM	Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B (Investopedia)
08:13AM	This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly (MarketWatch)
07:55AM	Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion (The Wall Street Journal)
07:01AM	This Stock Jumps 77% After $1.3 Billion Bid From Eli Lilly (Barrons.com)
06:45AM	Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk (PR Newswire)
05:54AM	Green energy stocks stumble, and other early market movers (MarketWatch)
05:33AM	Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. (Barrons.com)
Jun-16-25 07:49PM	Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push (Reuters)
Jun-13-25 12:00PM	What Makes Verve Therapeutics (VERV) a New Buy Stock (Zacks)
09:30AM	Loading…
Jun-06-25 09:30AM	Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average (Zacks) +8.12%
Jun-05-25 09:55AM	Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? (Zacks) +8.32%
Jun-02-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.75%
May-28-25 07:00AM	Verve Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks) -8.24%
May-14-25 08:15AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:11AM	Verve Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-13-25 05:20PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 06:05PM	Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +6.16% -5.58%
May-02-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.64%
Apr-29-25 07:53AM	1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street (Motley Fool)
Apr-19-25 07:40AM	What Moved Markets This Week (Seeking Alpha)
Apr-18-25 06:36PM	Why Verve Therapeutics Zoomed 40% Higher This Week (Motley Fool)
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks) -9.26%
10:56AM	Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' (Seeking Alpha)
Apr-15-25 12:43PM	Why Verve Therapeutics Is Skyrocketing Today (Motley Fool) +20.63%
12:27PM	VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study (Zacks)
Apr-14-25 04:12PM	Verves shares jump by more than 26% on Lilly-partnered gene therapy data (Pharmaceutical Technology) +26.38%
01:27PM	This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. (Barrons.com)
07:03AM	Verves second swing at gene editing for heart disease shows early promise (BioPharma Dive)
07:00AM	Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 (GlobeNewswire)
Apr-11-25 07:00AM	Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 (GlobeNewswire) +6.89%
Apr-04-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.85% -7.73%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.52%
10:27AM	Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? (Insider Monkey)
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-25-25 07:28AM	Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts (SeekingAlpha)
Mar-24-25 12:00PM	Verve gets FDA green light to expand base editing trial into US (BioPharma Dive)
07:00AM	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose (GlobeNewswire)
Mar-03-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:25AM	Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Verve Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
06:57AM	Vertex ends gene editing research pact with Verve (BioPharma Dive)
Feb-03-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.18%
Jan-29-25 07:00AM	Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire) +6.21%
Jan-23-25 09:31AM	Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? (Zacks)
Jan-13-25 07:00AM	Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones (GlobeNewswire)
Jan-08-25 07:00AM	Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.39%
Jan-03-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-30-24 03:29PM	Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) -7.97%
Dec-29-24 06:34AM	Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-29-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +27.63%
Nov-05-24 08:15AM	Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.45%
07:13AM	Verve Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-01-24 04:26PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-24 10:00AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
Oct-23-24 10:00AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
Oct-16-24 05:01PM	State Street Corp's Strategic Acquisition in Verve Therapeutics (GuruFocus.com)
Oct-11-24 06:15AM	Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERV (PR Newswire)
Oct-03-24 04:56AM	Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5? (Insider Monkey)
Oct-02-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:15AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
Sep-20-24 04:40PM	Jim Cramer on Vertiv Holdings (VRT): I Think Its A Winner (Insider Monkey)
Sep-12-24 01:15AM	Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc (GuruFocus.com)
Sep-08-24 04:51PM	Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers (Insider Monkey)
11:49AM	10 Worst ARK Stocks To Buy According To Short Sellers (Insider Monkey)
Sep-05-24 08:30AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire) -9.34%
Sep-03-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.25%
Aug-08-24 10:00AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
08:40AM	Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:47AM	Verve Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-02-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.24% -5.39%
Jul-08-24 07:07PM	Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now? (Insider Monkey) +8.00% +10.76%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-01-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-28-24 07:00AM	Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors (GlobeNewswire)

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kathiresan Sekar	Chief Executive Officer	Apr 02 '25	Sale	4.15	9,822	40,761	346,686	Apr 03 05:00 PM
Nickerson Joan	Chief Administrative Officer	Apr 02 '25	Sale	4.15	2,777	11,525	17,420	Apr 03 05:00 PM
Ashe Andrew D.	See Remarks	Apr 02 '25	Sale	4.15	2,681	11,126	348,828	Apr 03 05:00 PM
Politi Jason	Chief Technical Ops. Off.	Apr 02 '25	Sale	4.15	3,235	13,425	14,226	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Apr 02 '25	Sale	4.15	3,350	13,903	13,280	Apr 03 05:00 PM
Lister Troy	Chief Scientific Officer	Apr 02 '25	Sale	4.15	2,189	9,084	6,952	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Dec 02 '24	Sale	5.64	555	3,130	5,380	Dec 03 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERV

Verve Therapeutics Inc

Upgrade your FINVIZ experience